To: Surekha Gangakhedkar[surekhag@theranos.com] Cc:

Sunny Balwani[sbalwani@theranos.com]; Daniel Young[dyoung@theranos.com]; Samartha Anekal[sanekal@theranos.com]

Elizabeth Holmes[/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE

GROUP/CN=RECIPIENTS/CN=EHOLMES] Sat 7/13/2013 10:59:39 PM (UTC) Sent:

Surekha:

From:

What are the results of the testing we did this week on the performance of the ELISAs on the 3 3.0s in anticipation of LDT validation?

Cytometry and GC LDT validation begins Monday; we need to do ELISA validation in parallel.

Elizabeth

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Avenue, Palo Alto, CA, 94304

650-838-9292 <u>www.theranos.com</u>
